The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 13, 2021
Filed:
Oct. 17, 2019
Applicant:
Delinia, Inc., Emeryville, CA (US);
Inventors:
Jeffrey Greve, Berkeley, CA (US);
Jungmin Kim, Berkeley, CA (US);
Niranjana Nagarajan, Oakland, CA (US);
John Cho, Stoneham, MA (US);
Assignee:
Delinia, Inc., Emeryville, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/20 (2006.01); C07K 14/55 (2006.01); C07K 14/54 (2006.01); C07K 16/28 (2006.01); A61P 29/00 (2006.01); A61P 21/00 (2006.01); A61P 37/06 (2006.01); A61P 1/00 (2006.01); A61P 17/06 (2006.01); A61P 3/10 (2006.01); A61P 25/28 (2006.01); A61P 17/14 (2006.01); A61P 17/00 (2006.01); C12N 15/09 (2006.01); C07K 19/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/55 (2013.01); A61P 1/00 (2018.01); A61P 3/10 (2018.01); A61P 17/00 (2018.01); A61P 17/06 (2018.01); A61P 17/14 (2018.01); A61P 21/00 (2018.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); A61P 37/06 (2018.01); C07K 14/54 (2013.01); C07K 16/2866 (2013.01); C07K 19/00 (2013.01); C12N 15/09 (2013.01); A61K 38/00 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/71 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C07K 2319/74 (2013.01); C07K 2319/75 (2013.01);
Abstract
This disclosure provides compounds that contain an IL-2 receptor-binding moiety and an ST2-binding moiety. The methods described in the present disclosure provide for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound containing an IL-2 receptor-binding moiety and an ST2-binding moiety.